Stock Analysis
- South Korea
- /
- Medical Equipment
- /
- KOSDAQ:A376930
NoulLtd Third Quarter 2024 Earnings: ₩115 loss per share (vs ₩195 loss in 3Q 2023)
NoulLtd (KOSDAQ:376930) Third Quarter 2024 Results
Key Financial Results
- Net loss: ₩4.25b (loss narrowed by 8.8% from 3Q 2023).
- ₩115 loss per share (improved from ₩195 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
NoulLtd shares are down 13% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 4 warning signs for NoulLtd (2 make us uncomfortable!) that you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if NoulLtd might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSDAQ:A376930
NoulLtd
Engages in the in vitro diagnosis and remote diagnosis business worldwide.